Neko Health Body-Scan Startup Backed by Spotify's Ek Enters US

What happened

Neko Health, the full-body scanning startup backed by Spotify co-founder Daniel Ek, has expanded into the United States. The move was discussed on TechCrunch's Equity podcast by Farooq Abbasi, an investor in the company, who addressed the startup's momentum and its next steps as it takes its preventive health-scanning service beyond its European home market.

Neko Health operates clinics that use sensor- and camera-based scanning technology to assess a person's body and flag potential health risks, positioning itself as a preventive-care alternative to traditional check-ups. Its entry into the US market signals a new phase of growth for a company that has drawn significant attention — and investor interest — on the strength of its Spotify-linked founder and its bet on consumer-facing diagnostic technology.

Why it matters

Neko Health's US expansion is a notable test of whether a scan-based, data-driven health service built for one market can translate its experience model elsewhere. The company's proposition rests on making preventive diagnostics feel fast, visual and consumer-friendly rather than clinical — an approach that blends health technology with the kind of experience design more commonly associated with retail or hospitality.

For leaders across health tech, AI and digital transformation, the story is a reminder that consumer trust in sensor- and AI-assisted diagnostics is becoming a competitive battleground. How Neko Health adapts its service design, pricing and regulatory posture to the US will offer an early signal of how receptive American consumers are to this category of preventive, tech-enabled healthcare.

The Renascence take

The headline is the US launch, but the more interesting question is whether Neko Health can export the experience as faithfully as it exports the technology. Scanning hardware travels easily; trust, habit formation and perceived value do not.

Most coverage will focus on the funding pedigree and the novelty of full-body scanning, but the real test is behavioral: will US consumers, used to episodic and insurance-mediated care, adopt a proactive, pay-to-scan habit? Health-tech operators entering new markets should treat the first cohort of customers as a design lab — tracking not just clinical accuracy but how quickly people understand their results, trust the recommendation, and return. Get the explanation and follow-through experience wrong, and even the most sophisticated sensor stack won't survive contact with sceptical, cost-conscious consumers.